MERILOG Trademark
MERILOG is a USPTO trademark filed by Sanofi. Status: Pending.
Prosecution Summary
Trademark Summary
The standard character mark MERILOG covers pharmaceutical preparations for treating diabetes in International Class 005, with additional domestic classes 006, 018, 044, 046, 051, and 052. It is owned by Sanofi, a French corporation based in Paris. The intent-to-use application on the Principal Register awaits a Statement of Use, as a fourth extension of time was granted on May 6, 2025.
Recent Activity
Filed October 6, 2022, the mark was published for opposition on April 11, 2023, leading to a Notice of Allowance on June 6, 2023. Sanofi has filed four successive extensions for Statement of Use, with the latest granted May 6, 2025, and a Statement of Use received December 4, 2025.
Trademark Facts
| Mark | MERILOG |
|---|---|
| Serial Number | 97621322 |
| Status | Pending |
| Filing Date | 2022-10-06 |
| Mark Type | Word |
| Nice Classes | 005 (Pharmaceuticals) |
| Owner | Sanofi |
| Attorney of Record | Alexandra Kochian |
| Prosecution Events | 38 |
| Latest Event | SUPC on 2026-04-28 |
Goods & Services
Pharmaceutical preparations for treating diabetes